Slowing myopia progression in children
Medical hypothesis, discovery & innovation in optometry,
Vol. 5 No. 1 (2024),
30 April 2024
,
Page 43-50
https://doi.org/10.51329/mehdioptometry196
Abstract
Background: A large proportion of individuals develop myopia, which is recognized as a global health concern and is predicted to increase in prevalence. Long-term eye problems are associated with myopia, particularly in young individuals. Retinal detachment and choroidal degeneration are among the causes of visual impairments associated with myopia. In this narrative review, we summarized the current measures for slowing myopia progression in children, including their safety profiles and potential drawbacks.Methods: We conducted an English literature search for articles published between January 1, 2000, and October 31, 2023, using various combinations of keywords related to myopia, myopia progression, childhood myopia, myopia control, atropine, orthokeratology, and contact lenses. We included original or review articles pertaining to lifestyle changes and pharmacological, optical, or laser interventions for managing myopia progression in children. Our search was conducted using PubMed/MEDLINE, Google Scholar, and the Wiley Online Library. We reviewed the full text of included articles and qualitatively summarized the results of relevant studies using a narrative synthesis approach.
Results: Multiple meta-analyses indicated that increased outdoor time is associated with a lower myopia prevalence, with each extra hour spent outside each week reducing the risk of myopia by 2%. Candidate drugs, such as atropine, pirenzepine, and 7-methylxanthine, and certain intraocular pressure-lowering medications, such as timolol, have been studied in human trials for their ability to manage myopia. The nonselective antimuscarinic drug atropine, followed by the M1-selective antimuscarinic drug pirenzepine, displayed positive results in slowing myopia. Oral 7-methylxanthine, a nonselective adenosine receptor antagonist, reduces axial myopia caused by hyperopic defocus in a primate model. Low-intensity laser therapy using low doses of red and near-infrared light, visual biofeedback training, bifocal or multifocal spectacles, orthokeratology using a rigid gas-permeable contact lens, combined orthokeratology and atropine, soft contact lenses with a central distance zone and higher positive power in the periphery, and peripheral defocus contact lenses are among the interventional therapies with promising results in managing myopia progression in children.
Conclusions: The current literature supports the efficacy of increased outdoor time, administration of pharmacological agents, and special contact lenses as treatment modalities for slowing myopia progression in children. The effectiveness of orthokeratology alone and in combination with topical atropine therapy has also been assessed. Further research is needed to pinpoint the precise mechanisms of action of these therapies and to determine the best course of treatment. The increasing global prevalence of childhood myopia necessitates robust interventional studies into slowing myopia progression and preventing high myopia and related sight-threatening conditions in adulthood.
Keywords:
- nearsightedness
- myopias
- progressive myopia
- control
- children
- atropine sulfate
- pirenzepin
- orthokeratologic procedure
- pharmaceutical product
- Abstract Viewed: 0 times
- Full Text PDF Downloaded: 0 times